Wolfe Research initiated coverage of Janux Therapeutics (JANX) with a Peer Perform rating and no price target The firm believes additional work may be needed on JANX-007 before strong durability data materialize, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Positive Outlook on Janux Therapeutics Inc. Driven by Promising Prostate Cancer Developments and Strong Financial Position
- Janux Therapeutics price target raised to $46 from $45 at Stifel
- Janux Therapeutics price target raised to $48 from $47 at Barclays
- Buy Rating for Janux Therapeutics: Promising Data and Strong Financial Position Highlight Growth Potential
- Janux Therapeutics Reports Strong Financial Position Amid Clinical Advancements